Abstract

Omega-3 fatty acids have been suggested as a complement in cancer treatment, but doses are not established. We performed a dose-finding study in 33 children in remission from cancer. Participants were allocated to a body surface area (BSA) adjusted dose (mg/m2) of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (40:60), ranging 233-3448 mg/m2 daily for 90 days. Fatty acid concentration in plasma phospholipids and red blood cells were determined by GC. Supplementation was well tolerated and correlated strongly with blood o33fatty acid concentrations and EPA showed the highest increase. Using the o33-index disregards docosapentaenoic acid (DPA), which increased 30-43% in our study motivating an EDD-index ( n-ary sumation EPA,DPA,DHA). The ratio between arachidonic acid and EPA or DHA showed negative exponential trends. Dose per BSA enabled an individualized omega-3 supplementation decreasing the variation referred to interindividual differences. Based on our results, we suggest a dose of 1500 mg/m2 BSA for further studies.

Keywords

Docosahexaenoic acid; Eicosapentaenoic acid; Docosapentaenoic acid; Oleic acid; Arachidonic acid

Published in

Prostaglandins, Leukotrienes and Essential Fatty Acids
2021, Volume: 169, article number: 102285
Publisher: ELSEVIER SCI LTD

SLU Authors

• Pickova, Jana

  • Department of Molecular Sciences, Swedish University of Agricultural Sciences
    

Sustainable Development Goals

Ensure healthy lives and promote well-being for all at all ages


UKÄ Subject classification

Nutrition and Dietetics
Cell and Molecular Biology


Publication identifier

DOI: https://doi.org/10.1016/j.plefa.2021.102285

Permanent link to this page (URI)

https://res.slu.se/id/publ/112541